Systems Trichology

Raison d'être & About

A new era in hair loss management

We were founded with two core questions: Why, despite significant scientific advances, are only two drug treatments approved for hair loss? Can we translate cutting-edge research into real-world solutions that directly improve patient care?

Minoxidil

Finasteride

Developed from the 1950s-1970s, only minoxidil and finasteride are approved for AGA. They suffer from concerns regarding side effects and limited duration of effectiveness respectively, and options like Nutrafol remain untested for chronic and progressive hair loss. The status quo has failed patients.

80 million affected in US

80 years of research

2 outdated drugs approved

0 approvals since 1997

Why Now: Breakthroughts in Hair Loss Research

Since finasteride’s approval in 1997, advancements in hair loss science have surged. Yet, these insights remain underutilized in the treatments available to patients today — until today.

Solution: Hyper-focused teams and world-class domain expertise exclusively developing pharmacology targetting chronic and progressive hair loss.

Dihydroberberine
ergothioneine
Procyanidin B2
Sulforaphane
Galactomannan

Dihydroberberine
ergothioneine
Procyanidin B2
Sulforaphane
Galactomannan

Dihydroberberine
ergothioneine
Procyanidin B2
Sulforaphane
Galactomannan

With co-founders Dr. Nicholas Sadgrove and David Barreto personally affected by hair loss, our mission is clear: to improve outcomes for those facing chronic, progressive hair loss that is most common in hair transplant patients. After four years of refinement, systemK11 presents several firsts in hair loss management care such as targeting hair follicle glucose metabolism, mitochondrial function, and TGF-beta 1 using superior ingredient purity, bioavailability and standardisation.